Alex Hammond

“So, it's been a few weeks since you posted or presented the full CELIA data at AAIC. I guess given it's been some time for you to digest reactions from the medical and regulatory community, what feedback have you been getting?”

“So can you remind us of your confidence level in AFib? I guess given the size and breadth of the labrexia program, it seems like there's potentially a wide set of outcomes between a clean win and miss.”

“So on Rotatrutide, how do you think about its profile in relation to direct-to-consumer? Do you think it's a good fit there, particularly that 4-milligram dose?”

“So, obviously, this year, you guys have had three new acquisition integrations running simultaneously alongside multiple commercial launches. So, I guess, like, how should we think about margins in the near term and the long term?”

“On Medicare access, can you walk us through your strategy to activate these patients? And when do you kind of see this playing out in terms of either maybe a 4Q dynamic or more of a 2027 as these patients pull through.”